Related by context. All words. (Click for frequent words.) 78 double blinded placebo 76 prospective randomized placebo 70 source audio magnetotellurics 69 randomized blinded placebo 69 prospective randomized multicenter 68 double blinded randomized 65 randomized blinded 64 active comparator 63 randomized multicenter 63 randomized placebo 63 multicentre randomized 63 randomized Phase III 62 APTIVUS 62 multicenter randomized double 62 Phase III confirmatory 62 Phase IIIb 62 Hepatocellular Carcinoma HCC 61 blind randomized placebo 61 prospective multicenter 61 multicenter randomized 61 multicenter multinational 61 controlled multicenter 60 RE LY ® 60 placebo controlled Phase III 60 Phase IIB 60 multicentre randomized double 60 BAY #-# 60 Randomized Evaluation 59 blinded randomized 59 CHAMPION PCI 59 CSAMT MT survey 59 BRIM2 59 Phase IIa trials 59 placebo controlled clinical 59 placebo controlled Phase 59 multicenter randomized placebo controlled 59 Phase Ib II 59 Sym# 58 Valsartan 58 ONTARGET 58 Multicenter Randomized Double 58 Phase III randomized 58 Prospective Randomized 58 placebo controlled randomized 58 Degarelix 58 Phase III randomized controlled 58 double blind placebo 58 blinded randomized placebo controlled 58 phase IIb clinical 58 LUMINATE 58 ADVANCE PD 58 fosbretabulin 58 Trandolapril 58 TMC# C# 58 phase IIa clinical 58 validated multidimensional 58 Phase III placebo controlled 58 chemotherapeutic regimen 58 phase IIb 58 dose escalation Phase 57 multicenter placebo controlled 57 Randomized Clinical Trial 57 Phase Ib clinical 57 multicenter randomized clinical 57 Betaferon ® 57 BR.# 57 phase IIb trial 57 LCP AtorFen 57 Amrubicin 57 Rilonacept 57 icatibant 57 IL# PE#QQR 57 Starz Media www.starzmedia.com 57 intravesical infusion therapy 57 Matrix Phase 2b 57 MEVACOR 57 teriflunomide 57 prospective randomized controlled 57 investigational protease inhibitor 57 multicenter clinical 57 randomized Phase IIb 57 Randomized Double blind 57 Aplidin R 57 Locteron ® 57 Phase III Clinical Trials 57 randomized double 56 randomized clinical 56 tasocitinib 56 label multicenter 56 Telmisartan 56 Randomised 56 dose escalation phase 56 multicenter Phase 56 randomized crossover 56 APTIVUS r 56 Phase Ib study 56 ROCKET AF 56 trials RCTs 56 liposomal formulation 56 Jedi Mouse 56 GSK# [001] 56 randomized controlled Phase 56 TAXUS ATLAS 56 Tumor Response 56 Randomized Double Blind Placebo 56 BRIM3 56 Pulmonary Arterial Hypertension 56 Darunavir 56 phase Ib 56 blind placebo 56 Initiated Phase 56 label multicenter Phase 56 crizotinib PF # 56 Sapacitabine 56 Phase III Pivotal 56 Traficet EN 56 nonrandomized 56 ovulation stimulation 56 SCH # 56 REG1 56 phase IIa 56 Tocilizumab 56 Randomized 56 EQUIP OB 56 prospective nonrandomized 56 Phase Ib 56 ZOLINZA 56 DU #b 56 Blinatumomab 56 ENDEAVOR IV 56 multicenter randomized controlled 56 confirmatory clinical 56 Silar Advisors LP 56 Xanafide 56 randomized controlled clinical 56 evaluating tivozanib 56 INCB# [001] 56 Phase IIa 56 Velcade bortezomib 56 irbesartan 56 Phase IIb III 55 subanalysis 55 tocilizumab 55 tacrolimus ointment 55 PRoFESS 55 MIRCERA 55 #:# randomization 55 Acute Ischemic Stroke 55 pharmacokinetic PK 55 multicenter phase 55 multicentre 55 EXPAREL TM 55 RE LY 55 Phase 2b clinical 55 Zenvia Phase III 55 glatiramer acetate 55 phase IIb study 55 Medidur TM FA 55 CANCIDAS 55 multicenter Phase II 55 AVOREN 55 PD LID 55 Afinitor everolimus 55 lorcaserin Phase 55 Enzastaurin 55 CYT# QbG# 55 reslizumab 55 GW# [003] 55 AeroLEF TM 55 AIR CF3 55 ToGA 55 Carfilzomib 55 prospective multicenter randomized 55 PEG INTRON R 55 pertuzumab 55 ZYBRESTAT fosbretabulin 55 Phase #b/#a 55 phase IIIb 55 AVERROES 55 Phase IIIb study 55 PRECiSE 55 randomized multicenter trial 55 Azedra 55 protein kinase inhibitor 55 innovative transmucosal 55 EOquin TM 55 Phase IIb clinical 55 pitavastatin 55 PREZISTA r 55 Ranolazine 55 CD# monoclonal antibody 55 trastuzumab emtansine T DM1 55 interferon beta 1b 55 RE MODEL 55 sunitinib malate 55 Phase IIA 55 Flamel Medusa R 55 randomized placebo controlled 55 AIM HIGH 55 Phase III VISTA 55 mertansine 55 prospective multicentre 54 PRECISE 54 Teriflunomide 54 multicenter prospective 54 Pivotal Phase 54 Denufosol 54 dosing cohorts 54 Multicenter 54 fluticasone furoate 54 MoxDuo TM IR 54 ZD# [001] 54 dabigatran etexilate 54 EVEREST II 54 randomized controlled multicenter 54 MERLIN TIMI 54 Onrigin TM 54 HGS# 54 Adalimumab 54 MoxDuo 54 PRT# 54 cathepsin K inhibitor 54 HDAC Inhibitor 54 solved Simeon Varlamov 54 Phase III Clinical Trial 54 ENESTnd 54 Phase III clinical 54 Double Blind Placebo 54 miconazole Lauriad ® 54 MIST II 54 Phase 2a trial 54 Decitabine 54 Acute Decompensated Heart Failure 54 canakinumab 54 Taxotere ® 54 YONDELIS 54 allogeneic endothelial cells 54 EchoCRT 54 Microplasmin 54 stabilized RNA aptamer 54 multinational multicenter randomized 54 ISEL 54 SCIg 54 Tekturna HCT 54 REALITY Trial 54 Pivotal Trial 54 Dabigatran etexilate 54 zileuton 54 CCX# 54 Tanespimycin 54 AZILECT R 54 opioid induced bowel dysfunction 54 observer blinded randomized 54 Pazopanib 54 Phase III multicenter 54 ARCALYST ® rilonacept 54 Eculizumab 54 Methylnaltrexone 54 Tiotropium 54 Pharmacokinetic Study 54 PEG Intron ® 54 SPIRIT FIRST 54 ACTIVE W 54 cinacalcet 54 Phase 2a clinical 54 darunavir ritonavir 54 OLYMPIA registry 54 Phase 2b study 54 RE LY trial 54 FAME Study 54 PSMA ADC 54 decitabine 54 lacosamide 54 billionaire financier Edward Lampert 54 KB# [002] 54 paclitaxel poliglumex 54 Tarceva TM 54 ascending dose study 54 CONQUER OB 54 ancrod 54 EDEMA3 54 prospective randomized 54 Percutaneous Tibial Nerve Stimulation 54 Tolvaptan 53 Study Evaluating 53 PSN# [002] 53 Prostate AdenoCarcinoma Treatment 53 ASPIRE HIGHER 53 preclinical efficacy 53 prospective multicenter study 53 Left Ventricular Dysfunction 53 divalproex sodium 53 Phase 2b trial 53 HPTN 53 ongoing Phase 1b 53 Intervention Trial GAIT 53 PERSEUS 53 Phase IIIb clinical 53 subcutaneously administered 53 Phase 1b trial 53 prospective observational 53 dyskinesia PD LID 53 Phase IIb 53 ascending dose 53 multicenter Phase III 53 Phase IIa clinical 53 Multicenter Randomized 53 Phase 1b dose escalation 53 erlotinib Tarceva ® 53 eprotirome 53 CAMMS# 53 label multicenter randomized 53 multicenter 53 docetaxel Taxotere ® 53 GAMMAGARD 53 AIR CF1 53 Phase 1b clinical trials 53 RSD# 53 BENICAR HCT 53 MIVI III 53 clinical pharmacology studies 53 AIR2 Trial 53 ENVISION 53 Safinamide 53 pharmacokinetic PK profile 53 Stenting Trial CREST 53 randomized Phase 2b 53 herpetic keratitis 53 CIMZIA ™ 53 ZACTIMA 53 LUX Lung 53 Golimumab 53 TRANSFORMS 53 Double Blind Randomized 53 VICTOR E1 53 JAK inhibitor 53 European Sepsis Trial 53 direct thrombin inhibitors 53 RELOVAIR ™ 53 Spine Patient Outcomes 53 receptor tyrosine kinase inhibitor 53 MEK Inhibitor 53 acyclovir Lauriad R 53 Aortic Stenosis 53 thymalfasin 53 AIR CF2 53 MelaFind R 53 PFO migraine 53 PRE SURGE 53 MADIT II 53 RSD# oral 53 Investigator Initiated 53 thorough QT 53 Hydrogel Nanoparticle Aggregate 53 placebo controlled 53 huC# DM4 53 Phase IIb Trial 53 efalizumab 53 dose dose escalation 53 Placebo Controlled 53 TYKERB 53 intravitreal injection 53 docetaxel Taxotere R 53 tolerability pharmacokinetics 53 randomized 53 vinca alkaloid 53 metastatic HRPC 53 brivaracetam 53 clevidipine 53 Phase IIb randomized 53 6R BH4 53 assessing T DM1 53 Rosuvastatin 53 Apixaban 53 rilonacept 53 Phase #/#a 53 Cardiotoxicity 53 GATTEX ® 53 DAPT 53 Aflibercept 53 Phase IIb trial 53 randomized #:# 53 bolus dose 53 basal bolus regimen 53 galiximab 53 insulin detemir 53 Phase 2b randomized 53 Phase IIb IIIa 53 NEVO 53 RG# [001] 53 blind randomized 53 Sequenced Treatment Alternatives 53 Phase III 53 single ascending dose 53 confirmatory Phase III 53 AEG# 53 Phase 2b 53 Phase 1b clinical 53 beta2 agonist 53 GRN# 53 designated HVTN 52 NXL# 52 dose escalation trial 52 ritonavir boosted 52 APEX PD 52 dexpramipexole 52 IAP inhibitor 52 everolimus eluting stent 52 Alocrest 52 Edge STudy 52 BRAF inhibitor 52 gadobutrol 52 polymerase inhibitor 52 Randomized Double Blind 52 Linagliptin 52 Deforolimus 52 Randomized Phase 52 phase Ib clinical 52 EURIDIS 52 Phase 1a 52 PROSTVAC TM 52 EFAPROXYN 52 Clinical Antipsychotic Trials 52 latrepirdine 52 Daclizumab 52 randomized controlled 52 riociguat 52 oral dual endothelin 52 pen injectors 52 innovative Nanoflex TM 52 Tekturna HCT tablets 52 visilizumab 52 alvimopan 52 Pivotal Phase III 52 HCV SPRINT 52 REVLIMID lenalidomide 52 TAXUS Liberte Stent 52 ACTEMRA TM 52 ONTARGET R 52 Protelos 52 ReoPro 52 PRESEPT 52 relapsed MM 52 octreotide LAR 52 Long Lesion 52 somatostatin analog 52 MabCampath 52 EMPHASIS HF trial 52 Tekamlo 52 tipranavir 52 NO# [002] 52 eosinophilic asthma 52 pioglitazone HCl 52 ALGRX 52 Diamyd R 52 eribulin mesylate 52 oral ridaforolimus 52 Screening Trial 52 MEND CABG 52 pregabalin Lyrica 52 vidofludimus 52 serotonin norepinephrine reuptake inhibitor 52 CIMZIA TM 52 REVEAL Registry 52 subcutaneous formulation 52 microplasmin Phase III 52 cortical stimulation 52 Val HeFT 52 PROTEGE 52 Pivotal Study 52 sorafenib Nexavar ® 52 coadministration 52 Pegasys ® 52 ARIXTRA 52 ASTEROID 52 computerized numerically 52 TG MV 52 ORMD 52 Oral Fingolimod 52 VITAL Trial 52 Cloretazine 52 COSIRA trial 52 ACCORD Lipid 52 vapreotide acetate 52 oral rivaroxaban 52 concurrent chemoradiation 52 masked placebo controlled 52 tenofovir emtricitabine 52 PICSO ® 52 controlled multicenter Phase 52 Randomized Phase III 52 Mipomersen 52 HuMax EGFr 52 EGFR HER2 52 Phase 2a Clinical Trial 52 solithromycin 52 ENGAGE AF TIMI 52 rFVIIa 52 SNT MC# 52 NSABP B 52 MAGE A3 ASCI 52 KRN# 52 Micropump ® 52 Afatinib 52 antiepileptic drug 52 angiotensin receptor blocker ARB 52 IMPACT IMmunotherapy 52 sorafenib tablets 52 tezampanel 52 biliary tract cancer 52 backed Ustasha regime 52 neratinib 52 teriparatide 52 Mg Usa 52 fenretinide 52 desvenlafaxine succinate 52 ANCHOR trial 52 Phase IIb trials 52 AREDS 52 Cardiac Allograft Rejection 52 PEG SN# 52 ID NCT# 52 Investigational eFlow Nebulizer System 52 Multicenter Phase 52 fenofibric acid 52 ganetespib 52 VADT 52 MVA MUC1 IL2 52 multicenter study 52 TAXUS IV 52 sorafenib Nexavar 52 MKC# MKC# PP 52 tanespimycin 52 Patency 52 Quinamed 52 RezularTM 51 Infarct 51 II Clinical Trial 51 NLX P# 51 lane alternating flagger 51 label dose titration 51 tyrosine kinase inhibitor 51 cediranib 51 sitagliptin 51 SANTE 51 ADP receptor antagonist 51 Tracleer R 51 Elagolix 51 Phase #b/#a clinical 51 TRANSDUR ™ 51 FOLPI 51 CALGB 51 Androxal TM 51 Xeloda ® 51 Complications Trial 51 Dabigatran 51 Meets Primary Endpoint 51 HCV NS5B polymerase 51 pharmacokinetic PK study 51 dose escalation 51 HCD# [002] 51 exploratory endpoints 51 olmesartan 51 Dacogen injection 51 CIMZIA TM certolizumab pegol 51 CATIE AD 51 Triolex 51 GSK# [002] 51 Ixempra 51 Tyrima 51 IIa clinical 51 bortezomib Velcade R 51 pivotal bioequivalence 51 Elitek 51 multidose 51 dose titration 51 mGluR5 negative 51 Phase III metastatic melanoma 51 protease inhibitors PIs 51 low dose cytarabine 51 Daptomycin 51 MGd 51 PIX# [002] 51 CERVARIX 51 factorial design 51 Initiate Phase 51 FOSRENOL R 51 ISENTRESS 51 TMC# r 51 Intervention Effectiveness 51 pharmacokinetics PK 51 prucalopride 51 sunitinib Sutent ® 51 investigational humanized monoclonal antibody 51 rotigotine 51 Ozarelix 51 RGB # 51 GetGoal Phase III 51 NCT# ClinicalTrials.gov 51 rALLy clinical trial 51 clinical trial 51 treatment naive genotype 51 DIRECT Trial 51 nitazoxanide 51 Abciximab 51 myelofibrosis polycythemia vera 51 TAXUS V 51 Meta analyzes 51 ELONVA 51 VA# [002] 51 COPAXONE R 51 Randomized Phase II 51 comparator arm 51 LIALDA 51 pan HDAC inhibitor 51 Lomitapide 51 Phase Ia 51 mirtazapine 51 Prospective Randomized Trial 51 bevacizumab Avastin 51 unique alkylating agent 51 azacitidine 51 Seliciclib 51 ADAGIO study 51 Renal Cell Carcinoma RCC 51 Radiation Therapy Oncology 51 dosage regimens 51 sertraline Zoloft 51 telmisartan 51 Augment Injectable 51 Locteron 51 Controlled Trial 51 bevacizumab Avastin ® 51 randomized multicentre 51 ISIS # 51 Dapagliflozin 51 Prospective Multicenter 51 Monotherapy 51 pharmacodynamic profile 51 Rigel R# 51 Hycamtin ® 51 EmbraceAC 51 Chronic Heart Failure 51 FOLOTYN ® 51 Phase 2a 51 lucinactant 51 Phase Ib clinical trials 51 CLL8 51 blinded placebo controlled 51 CHARISMA trial 51 investigational HCV polymerase 51 CUSTOM III 51 confirmatory Phase 3 51 PROSTVAC ® 51 prospectively defined 51 SWOG 51 desvenlafaxine 51 bosentan 51 zolmitriptan 51 SUTENT ® 51 MYCAMINE 51 posaconazole 51 Embolic Protection 51 PreCISe 51 multiple ascending dose 51 Thrombolysis 51 drugs incorporating Contramid 51 laquinimod 51 rt PA 51 PROMACTA 51 trodusquemine 51 ABSORB trial 51 OMS# 51 topical formulation 51 pimecrolimus cream 51 oral prodrug 51 Phase #b/#a trial 51 intravenous dosing 51 Nord Trøndelag Health 51 sequential dose escalation 51 Glycemic Index prepared 51 FASLODEX 51 alpha blocker 51 aripiprazole 51 unfractionated heparin UFH 51 sodium glucose cotransporter 51 REVIVE Diabetes 51 interferon gamma 1b 51 boosted protease inhibitor 51 NATRECOR R 51 Relieve Depression STAR 51 Carotid Revascularization Endarterectomy vs. 51 nefazodone 51 ACTEMRA 51 highly selective inhibitor 51 Phase 2b Clinical Trial 51 NABTT 51 COMFORT II 51 phase 2a 51 external counterpulsation 51 EOquin TM phase 51 MADIT CRT 51 TAFA# 51 DEB# 50 Intravascular 50 IMC A# 50 vaccine ChronVac C 50 TG# [003] 50 Clolar ® 50 lenalidomide Revlimid R 50 biologic DMARD 50 paclitaxel Taxol ® 50 clozapine Clozaril 50 serum phosphorus 50 Voltaren ® 50 pharmacokinetics pharmacodynamics 50 Lymphocytic 50 MYDICAR ® 50 label dose escalation 50 tramiprosate Alzhemed TM 50 SRT# [003] 50 peripherally acting 50 Ovarian Cancer Screening 50 Phase 1a clinical 50 TKB# 50 mg/m2 cohort 50 protease inhibitor PI 50 Prostate Lung Colorectal 50 initiate multicenter 50 maximally tolerated dose 50 Zenvia ™ 50 non nucleoside inhibitor 50 ORACLE MS 50 TAXOTERE R 50 Pink Sheets JEDM 50 regorafenib 50 randomisation 50 landmark ATHENA 50 generation purine nucleoside 50 Ibritumomab Tiuxetan 50 both intercalates DNA 50 Phase IIb clinical trials 50 CARE HF 50 Endovascular Valve Edge 50 PREZISTA ritonavir 50 R#/MEM # 50 blinded placebo 50 Sibutramine Cardiovascular Outcomes 50 saquinavir ritonavir 50 randomized controlled clinical trials 50 dirucotide 50 ritonavir boosted lopinavir 50 ORENCIA ® 50 XIENCE V PROMUS Stent 50 Alpha Tocopherol Beta Carotene 50 investigational oral 50 diabetic neuropathic pain 50 bevirimat Study 50 dasatinib Sprycel ® 50 antihypertensive therapy 50 Therapy Evaluation 50 ENMD # 50 Radiofrequency Ablation 50 controlled dose escalation 50 Patient Outcomes 50 KAPIDEX 50 DermaVir Patch 50 RTP #i 50 Multaq R 50 Faropenem 50 trabedersen 50 Proellex TM 50 ceftazidime 50 Gabapentin GR 50 Estybon ™ 50 long acting muscarinic 50 randomized multicenter Phase III 50 PolyActive 50 Lodotra TM 50 administered subcutaneously 50 EORTC 50 metastatic RCC 50 Anturol TM 50 enzastaurin 50 cetuximab Erbitux R 50 Sorafenib HCC Assessment 50 Catheter Ablation 50 MIVI TRUST 50 multicenter dose escalation 50 MAXIMA 50 substudy 50 resminostat 50 Peptidomics 50 INVEGA ® 50 inhibitor RG# 50 Fludara 50 #mg doses [002] 50 Altera Nebulizer System 50 Systemic Sclerosis 50 ocular hypertension 50 statin simvastatin 50 Phase III Trial 50 confessionals Rodriguez 50 mapatumumab 50 Platelet Inhibition 50 prospectively randomized 50 VFEND 50 Navelbine ® 50 PREVAIL 50 Omacetaxine 50 Ridaforolimus 50 AVADO 50 Resten NG 50 ACZ# 50 saline placebo 50 abatacept 50 NVA# 50 pharmacokinetic studies 50 pharmacokinetic pharmacodynamic 50 BENICAR 50 aripiprazole Abilify 50 PRISTIQ 50 fostamatinib 50 Multiple Ascending Dose 50 relapsing multiple sclerosis 50 zonisamide SR 50 multicenter randomized Phase III 50 Placebo controlled 50 p# biomarker 50 Bayer HealthCare Onyx Pharmaceuticals 50 Phase IIa trial 50 Mr. Baldesarra 50 ECASS 50 dose escalation clinical 50 CLARITY study 50 tenofovir Viread 50 Endarterectomy 50 Pivotal Clinical Trial 50 metformin HCl 50 dose escalation study 50 alvespimycin 50 HCV RESPOND 2 50 R lenalidomide 50 Hydroxyurea 50 idraparinux 50 Halozyme Ultrafast Insulin 50 ProNeura technology 50 davunetide intranasal AL 50 Coronary Revascularization 50 Phase III trials 50 Dose Ranging Study 50 cetrorelix 50 multi kinase inhibitor 50 selective androgen receptor modulator 50 pegylated interferons 50 liposome injection 50 NICE SUGAR 50 ExTRACT TIMI 50 INCB# [003] 50 Advanced Renal Cell 50 unblinded 50 venlafaxine ER 50 IV bolus 50 multicenter randomized Phase 50 glycopyrrolate 50 oral antiviral 50 Diabetic Macular Edema 50 fluvastatin 50 EXPLORE Xa 50 DDP# 50 registrational trial 50 Specifically CompuFlo 50 CRLX# 50 TRITON TIMI 50 Parkinson disease levodopa induced 50 Relieve Depression 50 efavirenz EFV 50 HGS ETR2 50 registrational Phase 50 Tekturna HCT ® 50 MabThera rituximab 50 Long Term Efficacy 50 ENDEAVOR II 50 HeFT 50 topiramate Topamax 50 blind multicentre 50 viral kinetics 50 nonmetastatic prostate cancer 50 Randomized Study 50 Pharmacokinetic 50 Metastatic Prostate Cancer 50 dacarbazine 50 Pharmacokinetics PK 50 placebo controlled clinical trials 50 candesartan cilexetil 50 temsirolimus 50 LEXIVA r 50 multicentre prospective 50 Sipuleucel T 50 Acute Coronary Syndromes 50 SEROQUEL 50 See CLINICAL PHARMACOLOGY 50 lispro 50 lexidronam injection 50 ELND# 50 AKT inhibitor 50 CR# vcMMAE 50 Placebo Controlled Trial 50 safinamide 50 Controlled Study 50 stage IIIB 50 pivotal Phase III 50 migraine prophylaxis 50 Allovectin 7 ® 49 SUCCEED trial 49 Fx #A 49 EINSTEIN DVT 49 Naive Patients 49 relapsed refractory multiple myeloma 49 ABSORB clinical 49 Diabetic Nephropathy 49 ACRIN 49 Intrinsic Imaging 49 NGFN 49 Cervical Plate 49 neurogenic orthostatic hypotension 49 ataluren 49 Prograf ® 49 INSPIRE Trial Phase III 49 Severe Sepsis 49 depsipeptide 49 adipiplon 49 rilpivirine 49 GATTEX ™ 49 Tesmilifene 49 EDEMA4 49 Elotuzumab 49 deferiprone 49 paricalcitol 49 SYMMETRY trial 49 Xelox 49 Aggressive Drug Evaluation 49 albiglutide 49 DLTs 49 R# #mg BID 49 PREZISTA rtv 49 noninferiority 49 imetelstat 49 Critical Limb Ischemia CLI 49 Lamictal XR 49 SUTENT 49 Group RTOG 49 REMINYL ® 49 recurrent glioblastoma multiforme 49 Serious Adverse Events 49 PROPEL trial 49 BioNumerik 49 CRx 49 pharmacodynamics PD 49 anti arrhythmic 49 placebo controlled studies 49 PRTX 49 brand ciclesonide HFA 49 Testosterone MDTS ® 49 pharmacodynamics 49 IMPACT DCM 49 IIa trial 49 ThermoDox R 49 colesevelam HCl 49 risperidone Risperdal 49 Bivalirudin 49 Rasilez Tekturna 49 teduglutide 49 AEGR 49 Panitumumab 49 CK # administered 49 Zavesca R 49 By JENNIFER LEARN 49 Stent Coating 49 familial amyloidotic polyneuropathy FAP 49 docetaxel chemotherapy 49 OPT CHF 49 celgosivir 49 MIRAPEX ER 49 factor Xa inhibitor 49 DURATION 49 goserelin 49 dose cohorts 49 Phase III clinical trials 49 TYGACIL 49 abacavir Ziagen 49 μg dose 49 XL# SAR# 49 Phase 1b 49 STRIDE PD 49 SINGULAIR 49 DASISION 49 retrospective observational study 49 FOSRENOL ®